Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

This study is testing whether monitoring urine for tumor DNA (genetic material shed by cancer cells) can help reduce the need for frequent invasive surveillance procedures in people with high-risk non-muscle-invasive bladder cancer who have responded well to initial treatment. **You may be eligible if...** - You have high-risk non-muscle-invasive bladder cancer (confined to the bladder lining) - You have completed an induction course of BCG or gemcitabine/docetaxel treatment - Your post-treatment assessment (cystoscopy and urine tests) came back negative for cancer **You may NOT be eligible if...** - You have had high-risk bladder cancer within the past 3 years - You have had prior bladder instillation therapy - Your cancer is of an unusual (variant) cell type - You have concurrent cancer in the upper urinary tract (kidney or ureter) Talk to your doctor to see if this trial is right for you.